Abstract 199P
Background
To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiothery(CCRT) in patients with locally advanced esophageal squamous cell carcinoma(ESCC).
Methods
From May 2017 to February 2021, 90 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB:only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiothery (CCRT)(intervention group; n=44) and concurrent chemoradiothery (CCRT)(control group; n=46). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival(OS). The secondary end-points were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).
Results
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 67 patients (74%) had stage III and IV disease. The Endostar-combined group had a significant higher complete response rate(ORR) than the control group((80% vs. 63.8%; P=0.084). Survival patients had a median follow-up of 51.5 months(interquartile range: 48.2-54.8 months). The median overall survival were 16.7m in Endostar-combined group and 12.8m in control group, respectively(p=0.054). The Endostar-combined group had a significantly higher 5-year overall survival rate(13.6% vs 0%; p=0.014). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group(P>0.05).
Conclusions
This trial shows the combination of Endostar with concurrent chemoradiotheray (CCRT) was tolerable and provided higher ORR and 5-year overall survival rate over concurrent chemoradiothery (CCRT), and is very likely to provide promising survival benefit in patients with locally advanced ESCC.
Clinical trial identification
ChiCTR-IPR-16009926.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract